Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinovac and LG announce China hepatitis vaccine deal
Sinovac and LG Life Sciences signed a letter of intent on May 12, 2005 to collaborate on their international and China sector marketing efforts and vaccine supply. “Signing
Sinovac and LG Life Sciences signed a letter of intent on May 12, 2005 to collaborate on their international and China sector marketing efforts and vaccine supply. “Signing
The $27.6 million was secured in a private placement led jointly by new investors Atlas Venture and Index Ventures. Current investors Bio Fund, Dansk Kapitalanlaeg, Danske Bank and
Writing in Plant Biotechnology Journal, Dr Patricia Obregon and colleagues from St George’s, University of London and researchers at the University of Warwick say they have overcome a
The data suggest that study participants on 800mg of Flurizan maintained more of their global function and activities of daily living than those on 400mg of Flurizan or
The research, reported in Nature Genetics, identifies a transporter, encoded by the gene, as a potential target for drugs to boost oxalate secretion in the gut and help
Schering AG said in a statement that it believes the all-cash offer of E77 per share “significantly undervalues” the company and its prospects. The official comment also stressed
The flu is bad enough for healthy people, but the disease can place a special burden on those with weakened immune systems, such as patients on chemotherapy. Indeed,
R&D expenses were $18.4 million for 2005 compared to $10.2 million 2004. The company said that his increase was primarily the result of the continued expansion of its
The results from the trial are a blow to the companies which are seeking to expand the approved usage of Plavix which is used to help keep platelets
Led by Dr Michael Lubbert, of the University of Freiburg Medical Center in Freiburg, Germany, researchers assessed the efficacy of decitabine retreatment on relapsing high-risk myelodysplastic syndrome (MDS)